Oligomycin A
Based on 60 publication(s) in Google Scholar
Oligomycin A (MCH 32), created by Streptomyces, acts as a mitochondrial F0F1-ATP synthase inhibitor, with a Ki of 1 μM; Oligomycin A shows anti-fungal activity.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.89%
- No. CAS: 579-13-5
- Fòrmula: C45H74O11
- Peso molecular:791.06
-
Almacenamiento:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-13966
2-Deoxy-D-glucoseGlycolysis Inhibitor -
HY-100410
FCCPOXPHOS Uncoupler -
HY-B1756
RotenoneMitochondrial Complex I Inhibitor -
HY-16592
Brefeldin AProtein Transport Inhibitor -
HY-100558
Bafilomycin A1V-ATPase Inhibitor -
HY-N0862
HarringtonineInfluenza Virus Inhibitor -
HY-N6782
OligomycinH+-ATP-Synthase Inhibitor -
HY-100941
CCCPOXPHOS Uncoupler -
HY-10219
RapamycinmTOR Inhibitor -
HY-B0215
AcetylcysteineMucolytic Agent -
HY-B1743A
Puromycin dihydrochlorideProtein Synthesis Inhibitor -
HY-50202
EtomoxirCPT1a Inhibitor
Publications Citing Use of MedChemExpress (MCE) Oligomycin A
More- Signal Transduct Target Ther. 2025 Dec 17;10(1):413. [Abstract]
- Nature. 2026 May;653(8114):548-557. [Abstract]
- Cell. 2026 Sep 11:S0092-8674(26)00996-7.
- Cell Metab. 2023 Jan 3;35(1):200-211.e9. [Abstract]
- Cell Res. 2021 Sep;31(9):980-997. [Abstract]
- Nat Metab. 2025 Apr 11. [Abstract]
- Nat Aging. 2025 May;5(5):831-847. [Abstract]
- Cell Stem Cell. 2023 Apr 6;30(4):450-459.e9. [Abstract]
- Bone Res. 2024 Aug 28;12(1):49. [Abstract]
- Nat Protoc. 2024 May;19(5):1311-1347. [Abstract]
- Nat Commun. 2025 Nov 25;16(1):11018. [Abstract]
- Nat Commun. 2022 Apr 6;13(1):1853. [Abstract]
- Redox Biol. 2025 Sep:85:103762. [Abstract]
- Redox Biol. 2024 May:71:103112. [Abstract]
- Mol Cell. 2023 Jun 15;83(12):2137-2147.e4. [Abstract]
- Adv Sci (Weinh). 2026 Jul;13(39):e20095. [Abstract]
- Adv Sci (Weinh). 2026 Apr;13(21):e13341. [Abstract]
- Cell Rep Med. 2024 Jun 18;5(6):101580. [Abstract]
- Nano Today. 1 June 2022.
- NPJ Precis Oncol. 2026 Apr 16. [Abstract]
- Proc Natl Acad Sci U S A. 2025 May 13;122(19):e2424796122. [Abstract]
- Dev Cell. 2024 Aug 5;59(15):1954-1971.e7. [Abstract]
- Apoptosis. 2026 Aug 23;31(9):215.
- BMC Med. 2025 Mar 31;23(1):189. [Abstract]
- Cell Mol Gastroenterol Hepatol. 2023;15(5):1255-1275. [Abstract]
- Clin Transl Med. 2021 Apr;11(4):e395. [Abstract]
- ACS Appl Mater Interfaces. 2025 Jun 25;17(25):36487-36496. [Abstract]
- Cell Rep. 2025 Nov 25;44(11):116496. [Abstract]
- Cell Rep. 2025 Nov 18;44(12):116577. [Abstract]
- Cell Rep. 2025 Aug 29;44(9):116199. [Abstract]
- Cell Rep. 2021 Sep 21;36(12):109739. [Abstract]
- Cell Prolif. 2026 Apr 27:e70216. [Abstract]
- PLoS Biol. 2021 Apr 27;19(4):e3001197. [Abstract]
- JCI Insight. 2026 Sep 15:e205218.
- Drug Des Devel Ther. 2023 Oct 25:17:3205-3218. [Abstract]
- Int J Mol Sci. 2022 Oct 15;23(20):12354. [Abstract]
- Sci Rep. 2025 Sep 25;15(1):32878. [Abstract]
- Cancer Sci. 2025 Jan;116(1):152-163. [Abstract]
- Sci Rep. 2021 Dec 14;11(1):23977. [Abstract]
- Stem Cells. 2023 Jun 15;41(6):628-642. [Abstract]
- Mol Cell Biochem. 2026 May 21. [Abstract]
- Poult Sci. 2025 Aug 26;104(11):105730. [Abstract]
- iScience. 2024 Nov 6;27(12):111336. [Abstract]
- iScience. 2023 Dec 8;27(1):108690. [Abstract]
- Cell Cycle. 2024 Feb;23(4):435-447. [Abstract]
- J Radiat Res Appl Sci. 2026 Apr 6;19(2):102378.
- J Leukoc Biol. 2022 Aug;112(2):299-311. [Abstract]
- Vet Microbiol. 2023 Apr:279:109674. [Abstract]
- Prostate. 2025 Oct 1. [Abstract]
- Nutr Cancer. 2020;72(4):696-707. [Abstract]
- Cell Physiol Biochem. 2018;48(6):2318-2336. [Abstract]
- STAR Protoc. 2025 Apr 23;6(2):103792. [Abstract]
- STAR Protoc. 2024 Jun 27;5(3):103159. [Abstract]
- bioRxiv. 2026 Aug 23.
- University of Rijeka. 2025.
- Heliyon. 2024 Feb 23;10(5):e26904. [Abstract]
- Research Square Print. September 9th, 2022.
- Elife. 2022 Jun 24;11:e74713. [Abstract]
- Oxid Med Cell Longev. 2022 Mar 18;2022:2513837. [Abstract]
- SSRN. 15 Sep 2021 .
Customer Validation & Images
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
-
Cell Imaging/Staining
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
Ver todos los productos específicos de isoformas Antibiotic
More
Actividad biológica
Descripciòn
IC50 & Target
Ki: 1 μM (F0F1-ATPase)[1]
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HCT-116 | IC50 |
0.9 μM
Compound: Oligomycin A
|
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 32942072] |
| HCT-116 | IC50 |
1 μM
Compound: Oligomycin A
|
Antitumor activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antitumor activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 32942072] |
| K562 | IC50 |
0.2 μM
Compound: Oligomycin A
|
Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 32942072] |
| K562 | IC50 |
0.2 μM
Compound: Oligomycin A
|
Antitumor activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antitumor activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 32942072] |
| SH-SY5Y | IC50 |
29 μM
Compound: Oligomycin A
|
Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability after 24 hrs by MTT assay
Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 27689727] |
In Vitro
Oligomycin A is a mitochondrial F0F1-ATPase inhibitor with a Ki of 1 μM. Oligomycin A shows cytotoxic to the NCI-60 cell lines, with GI50 of 10 nM. Oligomycin A also inhibits the activity of Triton X-100-solubilized ATPase with a Ki of 0.1 μM. Furthermore, Oligomycin A has anti-fungal activity[1]. Oligomycin A (2.4 μM) inhibits the ability of spermatozoa to achieve feasible in vitro capacitation (IVC), and also suppresses progesterone-induced in vitro acrosome exocytosis (IVAE) as well as the concomitant peaks of O2 consumption and ATP levels[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 579-13-5
-
Appearance Solid
-
Peso molecular 791.06
-
Fòrmula C45H74O11
-
Color White to off-white
-
SMILES
O=C(/C=C/[C@H](C)[C@@H](O)[C@H](C)C([C@H](C)[C@@H](O)[C@@H]1C)=O)O[C@@]([C@@H]2C)([H])[C@H](C)[C@@]3(CC[C@H](C)[C@H](C[C@H](O)C)O3)O[C@@]2([H])CC[C@@H](CC)/C=C/C=C/C[C@@H](C)[C@H](O)[C@@](C)(O)C1=O
-
Synonyms
MCH 32
-
Structure Classification
-
Initial Source
Streptomyces diastatochromogenes
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (60)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Disruption of heme homeostasis by nuclear receptor Nur77 induces pyroptosis through granzyme B-dependent GSDMC cleavage. [Abstract]2025 Dec 17;10(1):413. PMID: 41407678 -
Nature
2026 May;653(8114):548-557. PMID: 41851457 -
-
Cell Metab
Ultrasensitive sensors reveal the spatiotemporal landscape of lactate metabolism in physiology and disease. [Abstract]2023 Jan 3;35(1):200-211.e9. PMID: 36309010
Oligomycin A purchased from MedChemExpress. Usage Cited in: Cell Metab. 2023 Jan 3;35(1):200-211.e9. [Abstract]
Inhibition of oxidative phosphorylation using the complex I inhibitor rotenone or the complex V inhibitor oligomycin A (3.5 μM) resulted in increased extracellular and subcellular lactate levels due to compensatory upregulation of glycolysis.
-
Cell Res
The metabolite α-KG induces GSDMC-dependent pyroptosis through death receptor 6-activated caspase-8. [Abstract]2021 Sep;31(9):980-997. PMID: 34012073 -
Nat Metab
NK cell-derived IFNγ mobilizes free fatty acids from adipose tissue to promote early B cell activation during viral infection. [Abstract]2025 Apr 11. PMID: 40217117 -
Nat Aging
Mitochondria-enriched hematopoietic stem cells exhibit elevated self-renewal capabilities, thriving within the context of aged bone marrow. [Abstract]2025 May;5(5):831-847. PMID: 40050412 -
Cell Stem Cell
Highly efficient and rapid generation of human pluripotent stem cells by chemical reprogramming. [Abstract]2023 Apr 6;30(4):450-459.e9. PMID: 36944335 -
Bone Res
2024 Aug 28;12(1):49. PMID: 39198395 -
Nat Protoc
Comprehensive multiscale analysis of lactate metabolic dynamics in vitro and in vivo using highly responsive biosensors. [Abstract]2024 May;19(5):1311-1347. PMID: 38307980
Oligomycin A purchased from MedChemExpress. Usage Cited in: Nat Protoc. 2024 May;19(5):1311-1347. [Abstract]
Quantitative analysis of FiLa expression in cytosol (Oligo, 1 μM).
Oligomycin A purchased from MedChemExpress. Usage Cited in: Nat Protoc. 2024 May;19(5):1311-1347. [Abstract]
Fluorescent images of FiLa expressed in cytosol (Oligo, 1 μM).
Oligomycin A purchased from MedChemExpress. Usage Cited in: Nat Protoc. 2024 May;19(5):1311-1347. [Abstract]
After sequentially injecting Glucose (Glc, 1 mM), Oligomycin (Oligo, 1 μM, 20 min), and 2-deoxyglucose (2-DG, 50 mM) into HEK-293 cells (n = 9), extracellular acidification rate (ECAR) was measured using a Seahorse XF96 analyzer to perform glycolytic stress testing.
-
Nat Commun
Remission spectroscopy resolves the mechanism of action of bedaquiline within living mycobacteria. [Abstract]2025 Nov 25;16(1):11018. PMID: 41290674
Oligomycin A purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 25;16(1):11018. [Abstract]
OCR traces of HEK293T cells treated with 10 µM bedaquiline (BDQ), ethanol vehicle control (EtOH), and 1.5 µM Oligomycin A for 5 min. Arrow indicates the time point at which drug was added.
-
Nat Commun
2022 Apr 6;13(1):1853. PMID: 35388015 -
Redox Biol
Activation of sclerostin inhibits Isg20-Mediated aerobic glycolysis ameliorating renal Fibrosis: the renoprotective mechanism of hederagenin in CKD. [Abstract]2025 Sep:85:103762. PMID: 40644925 -
Redox Biol
Enteric coronavirus PDCoV evokes a non-Warburg effect by hijacking pyruvic acid as a metabolic hub. [Abstract]2024 May:71:103112. PMID: 38461791 -
Mol Cell
2023 Jun 15;83(12):2137-2147.e4. PMID: 37244256 -
Adv Sci (Weinh)
2026 Jul;13(39):e20095. PMID: 41972457 -
Adv Sci (Weinh)
Single-Mitochondrion ATP Profiling Directs Discovery of Targetable OXPHOS Dependency in Cancers. [Abstract]2026 Apr;13(21):e13341. PMID: 41684301 -
Cell Rep Med
Venetoclax acts as an immunometabolic modulator to potentiate adoptive NK cell immunotherapy against leukemia. [Abstract]2024 Jun 18;5(6):101580. PMID: 38776913 -
-
NPJ Precis Oncol
Mitochondrial translocation of MDM2 and TFAM reprograms metabolism in treatment-refractory cancers. [Abstract]2026 Apr 16. PMID: 41991605 -
Proc Natl Acad Sci U S A
2025 May 13;122(19):e2424796122. PMID: 40327688 -
Dev Cell
2024 Aug 5;59(15):1954-1971.e7. PMID: 38776924 -
-
BMC Med
Enhancing anti-CD3 mAb-mediated diabetes remission in autoimmune diabetes through regulation of dynamin-related protein 1(Drp1)-mediated mitochondrial dynamics in exhausted CD8+T-cell subpopulations. [Abstract]2025 Mar 31;23(1):189. PMID: 40165248 -
Cell Mol Gastroenterol Hepatol
Gut microbiota-derived glutamine attenuates liver ischemia/reperfusion injury via macrophage metabolic reprogramming. [Abstract]2023;15(5):1255-1275. PMID: 36706918 -
Clin Transl Med
FABP4 deactivates NF-κB-IL1α pathway by ubiquitinating ATPB in tumor-associated macrophages and promotes neuroblastoma progression. [Abstract]2021 Apr;11(4):e395. PMID: 33931964 -
ACS Appl Mater Interfaces
Peptide Hydrogels for Renal Carcinoma Therapy via Synergistic Inhibition of Glycolysis and Mitochondrial Metabolism Reprogramming. [Abstract]2025 Jun 25;17(25):36487-36496. PMID: 40518708 -
Cell Rep
A generalized strategy to kill leukemic cells by targeting the regulatory systems governing mitochondrial membrane potential. [Abstract]2025 Nov 25;44(11):116496. PMID: 41166305 -
Cell Rep
Blocking glycogen synthase 1 in white adipose tissue alleviates hypermetabolism following severe burn injury through inhibition of JAK2 by UDPG. [Abstract]2025 Nov 18;44(12):116577. PMID: 41259203 -
Cell Rep
PI5P4Kα promotes glucose and iron acquisition to support metabolic fitness in pancreatic cancer. [Abstract]2025 Aug 29;44(9):116199. PMID: 40884794 -
Cell Rep
DOT1L O-GlcNAcylation promotes its protein stability and MLL-fusion leukemia cell proliferation. [Abstract]2021 Sep 21;36(12):109739. PMID: 34551297 -
Cell Prolif
Dissection of Mitochondrial Function via Chemical Perturbation and Single-Cell Profiling. [Abstract]2026 Apr 27:e70216. PMID: 42044679 -
PLoS Biol
HMGCR inhibition stabilizes the glycolytic enzyme PKM2 to support the growth of renal cell carcinoma. [Abstract]2021 Apr 27;19(4):e3001197. PMID: 33905408 -
-
Drug Des Devel Ther
Dexmedetomidine Ameliorates Cardiac Ischemia/Reperfusion Injury by Enhancing Autophagy Through Activation of the AMPK/SIRT3 Pathway. [Abstract]2023 Oct 25:17:3205-3218. PMID: 37908314 -
Int J Mol Sci
Modulating p-AMPK/mTOR Pathway of Mitochondrial Dysfunction Caused by MTERF1 Abnormal Expression in Colorectal Cancer Cells. [Abstract]2022 Oct 15;23(20):12354. PMID: 36293209 -
Sci Rep
2025 Sep 25;15(1):32878. PMID: 40998896 -
Cancer Sci
Noncanonical TCA cycle fosters canonical TCA cycle and mitochondrial integrity in acute myeloid leukemia. [Abstract]2025 Jan;116(1):152-163. PMID: 39479926 -
Sci Rep
2021 Dec 14;11(1):23977. PMID: 34907219 -
Stem Cells
Basic fibroblast growth factor promotes mesenchymal stem cell migration by regulating glycolysis-dependent β-catenin signaling. [Abstract]2023 Jun 15;41(6):628-642. PMID: 36951300 -
Mol Cell Biochem
UCHL1-mediated deubiquitination of GLOD4 regulates mitochondrial homeostasis and PTC malignant progression via GLO1. [Abstract]2026 May 21. PMID: 42166003 -
Poult Sci
Exploring ANT1 dysfunction as a pathological driver of wooden breast myopathy in broiler chickens. [Abstract]2025 Aug 26;104(11):105730. PMID: 40972420 -
iScience
Tracking fructose 1,6-bisphosphate dynamics in liver cancer cells using a fluorescent biosensor. [Abstract]2024 Nov 6;27(12):111336. PMID: 39640569 -
iScience
Prenatal hormone stress triggers embryonic cardiac hypertrophy outcome by ubiquitin-dependent degradation of mitochondrial mitofusin 2. [Abstract]2023 Dec 8;27(1):108690. PMID: 38235340 -
Cell Cycle
SIRT3 suppression resulting from the enhanced β-catenin signaling drives glycolysis and promotes hypoxia-induced cell growth in hepatocellular carcinoma cells. [Abstract]2024 Feb;23(4):435-447. PMID: 38626328 -
-
J Leukoc Biol
Bone marrow microenvironment drives AML cell OXPHOS addiction and AMPK inhibition to resist chemotherapy. [Abstract]2022 Aug;112(2):299-311. PMID: 34927743 -
Vet Microbiol
Porcine reproductive and respiratory syndrome virus infection manipulates central carbon metabolism. [Abstract]2023 Apr:279:109674. PMID: 36739813 -
Prostate
MEIS2 Modulates Oxidative Phosphorylation and ROS Generation to Affect CD8+ T Cell Antitumor Immunity in Prostate Cancer. [Abstract]2025 Oct 1. PMID: 41031828 -
Nutr Cancer
Metabolic Alterations Induced by Kudingcha Lead to Cancer Cell Apoptosis and Metastasis Inhibition. [Abstract]2020;72(4):696-707. PMID: 31352802 -
Cell Physiol Biochem
2018;48(6):2318-2336. PMID: 30114709 -
STAR Protoc
Protocol for real-time glycolytic monitoring in mammalian cells using confocal microscopy and HYlight, a biosensor for fructose 1,6-bisphosphate. [Abstract]2025 Apr 23;6(2):103792. PMID: 40279243 -
STAR Protoc
Protocol for real-time assessment of mitochondrial and glycolytic ATP production in patient-derived glioma stem-like cells. [Abstract]2024 Jun 27;5(3):103159. PMID: 38941182 -
-
-
Heliyon
eIF2α-mediated integrated stress response links multiple intracellular signaling pathways to reprogram vascular smooth muscle cell fate in carotid artery plaque. [Abstract]2024 Feb 23;10(5):e26904. PMID: 38434290 -
-
Elife
Metformin abrogates pathological TNF-α-producing B cells through mTOR-dependent metabolic reprogramming in polycystic ovary syndrome. [Abstract]2022 Jun 24;11:e74713. PMID: 35748536 -
Oxid Med Cell Longev
Ketone Body β-Hydroxybutyrate Prevents Myocardial Oxidative Stress in Septic Cardiomyopathy. [Abstract]2022 Mar 18;2022:2513837. PMID: 35340211 -
Solvente y solubilidad
In Vitro:
DMSO : 100 mg/mL (126.41 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Ethanol : 100 mg/mL (126.41 mM; ultrasonic and heat to 60°C)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.16 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (3.16 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.16 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% EtOH 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (3.16 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (293 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Salomon AR, et al. Apoptolidin, a selective cytotoxic agent, is an inhibitor of F0F1-ATPase. Chem Biol. 2001 Jan;8(1):71-80. [Content Brief]
[2]. Ramió-Lluch L, et al. Oligomycin A-induced inhibition of mitochondrial ATP-synthase activity suppresses boar sperm motility and in vitro capacitation achievement without modifying overall sperm energy levels. Reprod Fertil Dev. 2014;26(6):883-97. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / Ethanol | 1 mM | 1.2641 mL | 6.3206 mL | 12.6413 mL | 31.6032 mL |
| 5 mM | 0.2528 mL | 1.2641 mL | 2.5283 mL | 6.3206 mL | |
| 10 mM | 0.1264 mL | 0.6321 mL | 1.2641 mL | 3.1603 mL | |
| 15 mM | 0.0843 mL | 0.4214 mL | 0.8428 mL | 2.1069 mL | |
| 20 mM | 0.0632 mL | 0.3160 mL | 0.6321 mL | 1.5802 mL | |
| 25 mM | 0.0506 mL | 0.2528 mL | 0.5057 mL | 1.2641 mL | |
| 30 mM | 0.0421 mL | 0.2107 mL | 0.4214 mL | 1.0534 mL | |
| 40 mM | 0.0316 mL | 0.1580 mL | 0.3160 mL | 0.7901 mL | |
| 50 mM | 0.0253 mL | 0.1264 mL | 0.2528 mL | 0.6321 mL | |
| 60 mM | 0.0211 mL | 0.1053 mL | 0.2107 mL | 0.5267 mL | |
| 80 mM | 0.0158 mL | 0.0790 mL | 0.1580 mL | 0.3950 mL | |
| 100 mM | 0.0126 mL | 0.0632 mL | 0.1264 mL | 0.3160 mL |
Oligomycin A Related Classifications
HY-16589 Related Classifications
Powered by Bioz